Sumitomo Pharma Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

International Institute of Cancer Immunology, Inc.

Sumitomo Pharmaceuticals Company Limited

Boston Biomedical, Inc.

Sumitomo Dainippon Pharma Oncology, Inc.

Sumitomo Pharma Oncology, Inc.

Hitoshi Ban

Seiji Kamioka

Chiang Jia Li

Yosuke Takanashi

Wataru Hirose

Naoaki Shimada

Yusuke Sawayama

Masashi Goto

Yukihiro Nishio

Miki Hashizume

Futoshi Hasegawa

Manabu Kusagi

Yoshiaki Isobe

Hidenori Kimura

Hitoshi Watanabe

Shingo Tojo

Akihiko Arakawa

Kazuto Yamazaki

Kenjiro Hira

Toshio Nishihara

Atsushi Suwa

Masami Muraoka

Hiroki Umehara

Makoto Matsuoka

Kento Hayashi

Naohito Ohashi

Adam Siddiqui-Jain

Hiroki Yamaguchi

Hiroyuki Kitano

Tomoyuki Furuta

Yasushi Hiramine

Padma Malyala

Nobuyuki Sawada

Satoshi Ohnuma

Masayo Fujiwara

Natsuko Suginobe

Yusuke Imazaki

Yoshiko Iwata

Tsuguteru Otsubo

Shoukou Ri

Eiji Sugaru

Akihiko Yokoyama

Bilikallahalli K Muralidhara

Marcus Wong

The present invention provides a compound of the formula (1):

Substituted pyrimidines as vaccine adjuvants

The present invention relates to a compound useful as a vaccine adjuvant for cancer vaccine, a preparation process thereof, a pharmaceutical composition comprising the compound, and use of the compound as a vaccine adjuvant for cancer vaccine.

Water soluble adjuvant and composition containing same

The present disclosure provides a compound that exerts an anticancer action based on CHK1 inhibition. The present disclosure was completed by finding that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof exhibits an excellent antitumor action by having a potent inhibitory action against CHK1: wherein R, R, L, V, W, and Q are as defined herein, X, Y, and Z each independently represent CRor a nitrogen atom, wherein X, Y, and Z are not simultaneously CR, and Ris as defined herein.

5-heteroaryl-1H-pyrazol-3-amine derivative

The present invention relates to the compound of formula (I) wherein R, R, R, and Rare hydrogen atom, etc., Rand Rare hydrogen atom, etc., R, R, R, and Rare hydrogen atom, etc., L is bond, etc., V is Calkylene, Q is optionally-substituted imidazole, or a pharmaceutically acceptable salt thereof, as a novel anti-tumor agent that targets CSCs which are thought to be closely involved in the persistent proliferation of malignant tumor, metastasis or recurrence of cancer, and resistance to anti-tumor agents.

Dihydrochromene derivatives

The present application relates to WT1 helper peptides consisting of an amino acid sequence of 9 to 30 amino acid residues including a sequence: KLSHL as part thereof, and combinations of a WT1 helper peptide and a conjugate of cancer antigen peptides.

WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides

The compound of formula (1a) wherein p is 1 or 2, R-Rare hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.

Optically active azabicyclo ring derivative

Hemiasterlin derivative and antibody-drug conjugate thereof

A compound represented by formula (1): wherein

Hemiasterlin derivatives and antibody-drug conjugates including same

The present invention provides a compound of the formula (1): wherein X, R, R, R, R, R, R, Y, Y, L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.

A compound represented by formula (1-1): wherein b represents an integer of 1 to 5; and Z is a group represented by formula (Z-1), formula (Z-2), formula (Z-3), formula (Za-1), formula (Za-2), formula (Za-3), formula (Za-4) or formula (Za-5),or a salt thereof.

Antibody-drug conjugates including hemiasterlin derivative

A compound represented by the formula (1): wherein Xand Yare each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, Ris a hydrogen atom, a group represented by the formula (2): wherein Xand Yare each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.

WT1 antigen peptide conjugate vaccine

The present invention provides a 1,4-disubstituted imidazole derivative of formula (1') wherein ring Qis optionally-substituted Caryl group, etc.; Rand Rare independently hydrogen atom, etc.; Wis optionally-substituted Calkylene group; Wis &#x2014;NRC(O)&#x2014; wherein Ris hydrogen atom or Calkyl group, etc.; ring Qis 5- to 10-membered heteroaryl group, etc.; Wis optionally-substituted Calkylene group, etc.; n is 1, 2, 3, 4, or 5; Ris independently halogen atom, optionally-substituted Calkyl group, etc.; Ris hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent. 

1,4-disubstituted imidazole derivative

The present invention relates to the compound of formula (I) wherein R, R, R, and Rare hydrogen atom, etc., Rand Rare hydrogen atom, etc., R, R, R, and Rare hydrogen atom, etc., L is bond, etc., V is Calkylene, Q is optionally-substituted imidazole, or a pharmaceutically acceptable salt thereof, as a novel anti-tumor agent that targets CSCs which are thought to be closely involved in the persistent proliferation of malignant tumor, metastasis or recurrence of cancer, and resistance to anti-tumor agents. 

Growing community of inventors

Osaka, Japan

Hitoshi Ban